减少猜测,增加证据:识别晚期卵巢癌最不适合肿瘤细胞减灭术患者的分诊算法
本研究利用国家外科质量改进计划数据库,对2014至2017年间接受手术的1777例IIIC/IV期上皮性卵巢癌患者进行回顾性分析,验证了一种分诊算法。该算法将患者分为「高风险」和「分诊适当」两组,结果显示高风险组严重30天并发症或死亡风险显著更高(6.2% vs 3.5%,p=0.01),支持使用该算法个体化选择新辅助化疗或初次手术。
要点
- 该分诊算法可在多中心数据中识别术后并发症和死亡高风险的上皮性卵巢癌患者。
- 高风险组严重30天并发症或死亡率为6.2%,显著高于分诊适当组的3.5%。
- 客观手术风险评估应成为卵巢癌标准诊疗,可结合Mayo分诊算法实践。
核心结论
- 该分诊算法能利用全国多中心数据识别术后并发症和死亡高风险的上皮性卵巢癌患者。
- 初次肿瘤细胞减灭术达最小残留病灶仍是上皮性卵巢癌的目标。
- 客观手术风险评估应成为卵巢癌标准诊疗,并可通过Mayo分诊算法融入实践。
研究设计与样本
- 回顾性队列研究,使用国家外科质量改进计划数据库。
- 纳入2014年1月1日至2017年12月31日期间接受手术的IIIC/IV期上皮性卵巢癌女性。
- 共1777例患者符合纳入标准,平均年龄62.6岁,81.9%为IIIC期。
- 使用分诊算法将患者分类为「高风险」或「分诊适当」,采用卡方检验比较结局。
主要发现
- 全国范围内手术复杂度评分较低:69.8%低、25.2%中、5.0%高。
- 高风险组严重30天并发症或死亡率为6.2%,分诊适当组为3.5%(p=0.01)。
- 高风险组30天死亡率为1.4%,分诊适当组为0.5%(p=0.08)。
- 高风险组严重并发症后死亡风险为11.1%,分诊适当组为0%(p=0.11)。
- 排除未知白蛋白且不符合其他高风险标准的敏感性分析显示类似结果:严重30天并发症或死亡(6.2% vs 3.5%,p=0.02)和30天死亡率(1.4% vs 0.3%,p=0.04)。
关键数值与推荐
- 分诊算法将患者分类为「高风险」或「分诊适当」。
- 高风险组严重30天并发症或死亡率为6.2%,分诊适当组为3.5%(p=0.01)。
- 高风险组30天死亡率为1.4%,分诊适当组为0.5%(p=0.08)。
- 敏感性分析中高风险组30天死亡率为1.4%,分诊适当组为0.3%(p=0.04)。
临床怎么用
- 对于晚期上皮性卵巢癌患者,可使用Mayo分诊算法进行客观手术风险评估。
- 根据算法识别高风险患者,可能有助于个体化选择新辅助化疗或初次手术。
- 该算法在低手术复杂度环境中仍可识别高风险患者。
局限性
- 研究为回顾性设计,使用数据库数据。
- 全国手术复杂度评分普遍较低,可能影响结果外推。
- 使用30天死亡率而非90天死亡率。
- 部分患者白蛋白数据未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We previously reported an algorithm that identifies women at high risk of postoperative morbidity & mortality (M/M) as a tool to triage between neoadjuvant chemotherapy and primary surgery for epithelial ovarian cancer (EOC). We sought to independently validate its performance using multicenter data. METHODS: Women who underwent surgery for stage IIIC/IV EOC between 1/1/2014 and 12/31/2017 were identified from the National Surgical Quality Improvement Program database and classified as "high risk" or "triage appropriate" using our algorithm. Outcomes were compared between triage appropriate and high-risk women using the chi-square test. RESULTS: 1777 women met inclusion criteria; the mean age was 62.6 years and 81.9% had stage IIIC disease. Nationally, the surgical complexity scores were low (69.8% low, 25.2% intermediate and 5.0% high). "High risk" women had 2-fold higher rate of severe 30-day complication or death (6.2% vs 3.5%; p = 0.01), a 3-fold higher rate of 30-day mortality (1.4% vs 0.5%; p = 0.08), and a higher risk of death following a severe complication (11.1% vs. 0%, p = 0.11). A sensitivity analysis excluding women with unknown albumin who didn't meet other high risk criteria showed similar results: severe 30-day complications or death (6.2% vs 3.5%; p = 0.02) and 30-day mortality (1.4% vs 0.3%; p = 0.04) for "high risk" vs "triage appropriate" women. CONCLUSIONS: Primary cytoreductive surgery to minimal residual disease remains the goal for EOC. We verify that our algorithm can identify women at risk of M/M using national multicenter data, despite a low complexity surgical setting and using 30-day mortality (vs. 90-day). Objective surgical risk assessment for ovarian cancer should be standard of care and can be incorporated into practice using the Mayo triage algorithm.
引用
- Narasimhulu DM, Kumar A, Weaver AL, et al. Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management. Gynecol Oncol. 2020. PMID: 32247602. doi:10.1016/j.ygyno.2020.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。